TITLE

Enhanced posttransplant management of patients with diabetes improves patient outcomes

AUTHOR(S)
Keddis, Mira T; El Ters, Mireille; Rodrigo, Emilio; Dean, Patrick; Wohlfahrtova, Mariana; Kudva, Yogish C; Lorenz, Elizabeth C; Cosio, Fernando G
PUB. DATE
September 2014
SOURCE
Kidney International;Sep2014, Vol. 86 Issue 3, p610
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The survival of patients with diabetes mellitus in the general population has improved in recent years. Here we assessed whether similar trends have occurred in 1688 kidney recipients, including 413 with diabetes prior to transplant between 1996 and 2007. Compared to patients without diabetes, the 5-year mortality was significantly increased (hazard ratio (HR) 2.68 (1.95-3.69)) due to higher cardiovascular-, infection-, and malignancy-related deaths in those with diabetes. However, 5-year mortality in patients with diabetes significantly declined over time (HR 0.883 (0.817-0.954)), narrowing the mortality difference between patients with and those without diabetes and in more recent years largely eliminating it. Post transplant, patients with diabetes experienced a significant decline in major fatal/nonfatal cardiac events (HR 0.853 (0.782-0.930)) and infectious deaths over time. In contrast, neither cardiac events nor overall mortality declined in recipients without diabetes. The decline in mortality due to diabetes did not relate to a reduced pretransplant risk profile and was independent of posttransplant variables. The use of cardioprotective medications and glycemic control improved over time post transplant. Furthermore, graft function and serum albumin significantly improved over time and these parameters related to better survival (albumin, HR 0.365 (0.223-0.599); eGFR, HR 0.803 (0.756-0.852)). Thus, survival of kidney recipients with diabetes mellitus has improved markedly since 1996 likely reflecting, at least in part, enhanced posttransplant management and outcomes.
ACCESSION #
97803623

 

Related Articles

  • Arterial Stiffness Is Inversely Related to Plasma Adiponectin Levels in Young Normotensive Patients With Type 1 Diabetes. Tsiakou, Afroditi; Liatis, Stavros; Alexiadou, Kleopatra; Diakoumopoulou, Evanthia; Makrilakis, Konstantinos; Tentolouris, Nicholas; Kyriaki, Despoina; Katsilambros, Nicholas // Diabetes Care;Mar2013, Vol. 36 Issue 3, p734 

    OBJECTIVE -- This study investigated the association between arterial stiffness and plasma adiponectin in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS -- Participants were normotensive patients with type 1 diabetes who were up to age 40 years. Subjects on statins with macrovascular...

  • Recent Advances in diabetic nephropathy. Marshall, S. M. // Postgraduate Medical Journal;Nov2004, Vol. 80 Issue 949, p624 

    Diabetic nephropathy is the leading cause of end stage renal disease worldwide and is associated with increased cardiovascular risk. The earliest clinical manifestation is of microalbuminuria. Tight blood glucose and blood pressure control reduce the risk of microalbuminuria. Once...

  • Cardiac Autonomic Neuropathy Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy. Astrup, Anne Sofie; Tarnow, Lise; Rossing, Peter; Hansen, Birgitte V.; Hilsted, Jannik; Parving, Hans-Henrik // Diabetes Care;Feb2006, Vol. 29 Issue 2, p334 

    OBJECTIVE -- Cardiac autonomic neuropathy (CAN) has been associated with a poor prognosis in patients with diabetes. Because CAN is common in patients with diabetic nephropathy, we evaluated the predictive value of CAN in type 1 diabetic patients with and without diabetic nephropathy. RESEARCH...

  • Metabolic Syndrome as a Risk Factor for Cardiovascular Disease, Mortality, and Progression of Diabetic Nephropathy in Type 1 Diabetes. Thorn, Lena M.; Forsblom, Carol; Wadén, Johan; Saraheimo, Markku; Tolonen, Nina; Hietala, Kustaa; Groop, Per-Henrik // Diabetes Care;May2009, Vol. 32 Issue 5, p950 

    OBJECTIVE -- To assess the predictive value of the metabolic syndrome in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS -- Patients were from the prospective Finnish Diabetic Nephropathy (FinnDiane) Study (n = 3,783): mean age 37 ± 12 years and diabetes duration 23 ± 12 years....

  • Naturopathic Approaches to Diabetic Kidney Disease. Tan, Alex; Leone, Jacob // Townsend Letter;Feb/Mar2009, Issue 307/308, p96 

    The article focuses on naturopathic approaches to treating diabetic kidney disease. It discusses the processes that have been shown to reduce morbidity and mortality in diabetic nephropathy such as prevention, dietary and lifestyle interventions, and biologically-based interventions. It explains...

  • Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Gross, Jorge L.; De Azevedo, Mirela J.; Silveiro, Sandra P.; Canani, Luís Henrique; Caramori, Maria Luiza; Zelmanovitz, Themis // Diabetes Care;Jan2005, Vol. 28 Issue 1, p164 

    Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ∼40% of type 1 and type 2 diabetic patients. It increases the risk of death, mainly from cardiovascular causes, and is defined by increased urinary albumin excretion (UAE)...

  • The detection and measurement of microalbuminuria: a challenge for clinical chemistry. Busby, Douglas E.; Atkins, Robert C. // MLO: Medical Laboratory Observer;Feb2005, Vol. 37 Issue 2, p8 

    Focuses on the need for the early identification of microalbuminaria (MA) as a risk factor in diabetic nephropathy and cardiovascular disease (CVD). Percentage of the overall prevalence of MA in persons with a diagnosis of diabetes; Establishment of MA as strong, independent risk factor for CVD...

  • Outcome variables in the assessment of progression of diabetic kidney disease. Viberti, GianCarlo // Kidney International Supplement;Feb1994, Issue 45, pS-121 

    Focuses on the outcome variables in the assessment of progression of diabetic kidney disease. Use of surrogate endpoints in the evaluation of the progression of nephropathy; Correlation between glomerular structure and renal function in diabetes; Criteria for ascribing causality to the...

  • Effect of Telmisartan on Renal Outcomes. Mann, Johannes F. E.; Schmieder, Roland E.; Dyal, Leanne; McQueen, Matthew J.; Schumacher, Helmut; Pogue, Janice; Xingyu Wang; Probstfield, Jeffrey L.; Avezum, Alvaro; Cardona-Munoz, Ernesto; Dagenais, Gilles R.; Diaz, Rafael; Fodor, George; Maillon, Jean M.; Rydén, Lars; Yu, Cheuk M.; Teo, Koon K.; Yusuf, Salim // Annals of Internal Medicine;7/7/2009, Vol. 151 Issue 1, p1 

    Background: Angiotensin-receptor blockers (ARBs) blunt progression of advanced diabetic nephropathy, but their long-term renal effects in other patients are not clear. Objective: To examine the long-term renal effects of telmisartan versus placebo in adults at high vascular risk. Design:...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics